Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.

Ítems similars

• FDA's pathway for regulation of FMT: not so fraught
  per: Riley, Margaret F., et al.
  Publicat: (2015)
• FDA and EMA Biosimilar Approvals
  per: Jung, Emily H., et al.
  Publicat: (2019)
• Early Biosimilars Face Hurdles to Acceptance: The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High
  per: Barlas, Stephen
  Publicat: (2016)
• FDA Commissioner Outlines New Plan to Increase Biosimilars by Balancing Innovation and Competition
  per: Koutnik-Fotopoulos, Eileen
  Publicat: (2018)
• The Economics of Biosimilars
  per: Blackstone, Erwin A., et al.
  Publicat: (2013)